insect venom allergy
Immunology · 2016–2018
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| insect allergen extracts (honey bee venom, paper wasp venom, yellow jacket venom) Supply shortage management: temporary listings of substitute insect allergen extract products (honey bee venom, paper wasp venom, and yellow jacket venom… | Jul 2018 | Recommended | no section in document |
| insect allergen extract - honey bee venom, yellow jacket venom, paper wasp venom Replacement forms of currently listed bee venom, paper wasp venom, and yellow jacket venom products due to supply shortage. | Mar 2016 | Recommended | no section in document |
What the PBS pays
$0M in government benefit over 2024–25, across 454 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| insect allergen extract - honey bee venom, yellow jacket venom, paper wasp venom | $0.1M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.